Libby's H*O*P*E*

*Helping*Ovarian Cancer Survivors*Persevere Through*Education

Posts Tagged ‘The Johns Hopkins Medical Institutions’

NBOCC Run/Walk for Her — September 21, 2008

Posted by Paul Cacciatore on August 29, 2008

On Sunday, September 21, 2008, the National Breast and Ovarian Cancer Coalition (NBOCC) will conduct its annual 5K Run/3K Walk for Her. This walk is dedicated to those who have lost the battle to breast or ovarian cancer, and celebrates those who continue to fight. The event will start at 8:00 A.M. EDT and is being held at Quiet Waters Park, located in Annapolis, Maryland.

2008 NBOCC Run/Walk for Her

On Sunday, September 21, 2008, the National Breast and Ovarian Cancer Coalition (NBOCC) will conduct its annual 5K Run/3K Walk for Her. This walk is dedicated to those who have lost the battle to breast or ovarian cancer, and celebrates those who continue to fight. Libby’s H*O*P*E*™ would like to thank Paula Kozik (an inspirational ovarian cancer survivor and volunteer organizer of the Run/Walk for Her event) for dedicating her walk in this event to Elizabeth (Libby) Remick.

The event will start at 8:00 A.M. EDT and is being held at Quiet Waters Park, located in Annapolis, Maryland.

  • For online registration, CLICK HERE.
  • For a copy of the 2008 NBOCC Run/Walk for Her brochure, CLICK HERE.
  • The event schedule and additional details are listed below.

8:00 A.M.

Registration- Red Maple Pavilion

NBOCC Run/Walk for HER - Breast & Ovarian Cancer Survivors

NBOCC Run/Walk for HER - Breast & Ovarian Cancer Survivors

On-site registration
Pre-registered walkers/runners
Pick up t-shirt and program

8:30 A.M.

Survivor Hand Banner

8:45 A.M.

Survivor Group Photos

9:00 A.M.

Warm Up, Run/Walk Begins

10:00 A.M.

Closing Ceremonies

Prices:

Quiet Waters Park, Annapolis, Maryland

Quiet Waters Park, Annapolis, Maryland

Adult – $35.00
Child Under 12 – $15.00

Online Registration Closes:

September 18, 2008 at 9:00 P.M.

Website:

http://www.NBOCC.org

About the NBOCC

The National Breast and Ovarian Cancer Coalition (NBOCC) is a growing non-profit organization dedicated to education, awareness and research developments for breast and ovarian cancer. Specifically, the mission of NBOCC is to raise awareness and educate the general public about the link between breast and ovarian cancer.

The founder and executive director of NBOCC is Nikki Karl. Nikki is a lifelong supporter of the fight against breast and ovarian cancer. She established the National Ovarian Cancer Coalition (NOCC) Maryland Chapter in November 2003. However, having lost ten family members to breast and ovarian cancer, she realizes the importance of pairing these two diseases together so that women may understand the potentially life-saving facts regarding hereditary breast and ovarian cancer. NBOCC is dedicated to Nikki’s grandmother, who died of ovarian cancer, and her mother, who is a breast cancer survivor.

Notably, Robert E. Bristow, M.D., is a board member of, and the chief medical advisor to, NBOCC. Dr. Bristow serves as Director of the Kelly Gynecologic Oncology Service Department of Gynecology and Obstetrics at The Johns Hopkins Medical Institutions (Johns Hopkins), as well as the Johns Hopkins Ovarian Cancer Center of Excellence. His primary research interests include radiographic imaging of gynecologic cancers, the surgical management of cancers of the ovary and endometrium, and patterns of health care delivery for women with gynecologic cancer. In addition to having received numerous awards for teaching excellence, Dr. Bristow directs the American Board of Obstetrics and Gynecology approved F. J. Montz Fellowship Training Program in Gynecologic Oncology at the Johns Hopkins Hospital and Greater Baltimore Medical Center. On July 10, 2008, U.S. News & World Report ranked Johns Hopkins as the #1 U.S. hospital (defined by highest scores in at least six medical specialties), #2 U.S. gynecology practice, and #3 U.S. oncology practice.

Posted in Fund-Rasing Event | Tagged: , , , , , , , , , , | 1 Comment »

TP53 Gene Mutation Found in 80% of High Grade Ovarian Serous Carcinomas; TP53 Not Directly Involved In The Development of Drug Resistance

Posted by Paul Cacciatore on July 21, 2008

“… [T]he [Johns Hopkins] research team concluded that the frequency of TP53 gene mutations using purified tumor DNA from ovarian serous carcinomas was 80.3%, which is much higher than previously reported in the medical literature. Furthermore, the research team found that TP53 is not directly involved in the development of drug resistance in high-grade ovarian serous carcinomas.”

The TP53 gene mutation frequency in ovarian serous carcinomas has been reported to range between 50% and 80%. A research team working at the The Sidney Kimmel Comprehensive Cancer Center of The Johns Hopkins Medical Institutions (Johns Hopkins) made several important findings regarding TP53 gene mutations with respect to high grade ovarian serous carcinoma, as reported in the International Journal of Gynecological Cancer. Ovarian serous carcinoma is the most common tumor subtype within the epithelial ovarian cancer histological classification.

According to the Johns Hopkins research team, a stringent analysis of the TP53 gene using purified epithelial tumor samples has not been performed to accurately assess the TP53 gene mutation frequency and its correlation to tumor histologic grade. The research team assessed the TP53 gene mutational profile in a relatively large series of high-grade (53 primary tumors and 18 recurrent tumors) and 13 low-grade ovarian serous tumors. All samples were affinity purified, and the tumor DNA was analyzed for TP53 mutations in exons 4 through 9. In addition, the ovarian serous tumors were subjected to in vitro drug resistance testing. In vitro drug resistance assays were performed on the same tumor samples using carboplatin, cisplatin, paclitaxel, and taxotere, and the results were correlated with the TP53 mutation status.

The reported study findings are as follows:

  • TP53 mutations were detected in 57 (80.3%) of 71 high-grade carcinomas and in one (7.8%) of 13; low-grade serous tumors (an invasive low-grade serous carcinoma);
  • The mutations were predominantly missense mutations (59.6%);
  • TP53 mutations were associated with high-grade serous carcinomas and recurrent disease; and
  • There was no statistically significant correlation between TP53 mutation status and drug resistance assays or clinical stage.

Accordingly, the research team concluded that the frequency of TP53 gene mutations using purified tumor DNA from ovarian serous carcinomas was 80.3%, which is much higher than previously reported in the medical literature. Furthermore, the research team found that TP53 was not directly involved in the development of drug resistance in high-grade ovarian serous carcinomas.

Source: Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance; Salani R, et. al., Int J Gynecol Cancer. 2008 May-Jun;18(3):487-91. Epub 2007 Aug 10.

Posted in Genetics, Medical Study Results, Proteomics | Tagged: , , , , , , | Leave a Comment »

 
Follow

Get every new post delivered to your Inbox.

Join 2,011 other followers

%d bloggers like this: